50606-31-0

Basic information

• Product Name: METHYL PIPERAZINE-1-CARBOXYLATE
• Synonyms: METHYL PIPERAZINE-1-CARBOXYLATE;Methylpiperazine-1-carboxylate ,97%;1-Piperazinecarboxylic acid, Methyl ester;Piperazine-1-carboxylic acid Methyl ester;Methyl piperazin-1-carboxylate
• CAS NO: 50606-31-0
• Molecular Formula: C₆H₁₂N₂O₂
• Molecular Weight: 144.17
• EINECS: 1533716-785-6
• Product Categories: pharmacetical
• Mol File: 50606-31-0.mol
• Article Data: 14

Chemical Properties

• Melting Point: 173-175 °C
• Boiling Point: 218.5 ºC at 760 mmHg
• Flash Point: 85.9 ºC
• Appearance: /
• Density: 1.099 g/cm³
• Vapor Pressure: 0.125mmHg at 25°C
• Refractive Index: 1.465
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.45±0.10(Predicted)
• CAS DataBase Reference: METHYL PIPERAZINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL PIPERAZINE-1-CARBOXYLATE(50606-31-0)
• EPA Substance Registry System: METHYL PIPERAZINE-1-CARBOXYLATE(50606-31-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 50606-31-0(Hazardous Substances Data)

Usage

Description

METHYL PIPERAZINE-1-CARBOXYLATE, also known as 1-(Methoxycarbonyl)piperazine, is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its functional groups, including a carboxylate group and a piperazine ring, which contribute to its reactivity and potential applications in the medical field.

Uses

Used in Pharmaceutical Industry:
METHYL PIPERAZINE-1-CARBOXYLATE is used as a synthetic intermediate for the development of piperazine derivatives. These derivatives act as kinase inhibitors, which play a crucial role in the treatment of diabetes, diabetic complications, and other diseases. The inhibition of specific kinases can help regulate cellular processes and provide therapeutic benefits for patients suffering from these conditions.

InChI:InChI=1/C6H12N2O2/c1-10-6(9)8-4-2-7-3-5-8/h7H,2-5H2,1H3

Upstream product

• 110-85-0 piperazine 
• 17175-16-5 p-nitrophenyl methyl carbonate 
• 219509-79-2 1-(tert-butyl) 4-methyl piperazine-1,4-dicarboxylate 
• 383865-57-4 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine 
• 79-22-1 methyl chloroformate 
• 873697-75-7 methyl piperazine-1,3-carboxylate hydrochloride 

Downstream Products

• 7560-85-2 methyl 4-methylpiperazine-1-carboxylate 
• 873697-63-3 C₁₃H₁₇N₃O₄ 
• 942224-53-5 tert-butyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate 
• 873697-70-2 methyl 4-(3-amino-2-fluorobenzyl)piperazine-1-carboxylate 
• 873697-81-5 tert-butyl 4-(2-(3-nitrophenyl)acetyl)piperazine-1-carboxylate 
• 873697-72-4 C₁₃H₁₉N₃O₂ 
• 873697-71-3 methyl 4-[(2-fluoro-3-{[(6-methylpyridin-3-yl)carbamoyl]amino}phenyl)methyl]piperazine-1-carboxylate 
• 1309439-45-9 methyl 4-(3-chloro-2-fluorobenzyl)piperazine-1-carboxylate 
• 1391636-60-4 C₁₇H₂₃ClN₂O₄ 
• 1445901-18-7 4-{4-[(N-isobutyl-1-phenylmethylsulfonamino)methyl]phenyl}piperazine-1-carboxylic acid methyl ester 

Relevant articles and documents

ALTERNATE PROCESSES FOR THE PREPARATION OF OMECAMTIV MECARBIL

Aspects of the present application relate to process for the preparation of Omecamtiv mecarbil and salts thereof. Specific aspects relate to novel urea intermediate, preparative process thereof and its use in the preparation of Omecamtiv mecarbil and salts thereof. The improved process for the preparation of Omecamtiv mecarbil are industrially viable.

Development of a Factory Process for Omecamtiv Mecarbil, a Novel Cardiac Myosin Activator

The development of a factory process to manufacture the novel cardiac myosin activator omecamtiv mecarbil (1) is described. Omecamtiv mecarbil is prepared via the convergent synthesis and coupling of two key fragments, aniline 2 and carbamate 4-HCl, which serves as a masked isocyanate. To enable practical access to aniline 2, reduction of the corresponding nitroaromatic was designed to control potential mutagenic impurities. Key to the efficient preparation of 2 was the benzylic bromination of 8 followed by selective debromination of a gem-dibromide byproduct and subsequent alkylation with 5-phosphate. Overall, the longest linear sequence consists of six steps, including a final salt formation step to afford the drug substance in 55% overall yield. Because of poor performance of the original free-base form of the drug substance in modified-release formulations, an improved dihydrochloride hydrate form was developed to aid drug product performance and manufacturability.

Unsymmetrical tetrasubstituted ureas from tertiary carbamoylimidazole: Activation by AlMe3

An efficient and general method for the synthesis of unsymmetrical tetrasubstituted ureas from carbamoylimidazole is described. The conversion is achieved by the concurrent quarternization of the imidazole nitrogen and activation of amines with AlMe3. The Royal Society of Chemistry 2012.